George A Scangos has sold stock and made no open-market buys since Feb 2016

George A. Scangos, Ph.D. is a biotechnology executive and corporate insider best known as the founding president and chief executive officer of Vir Biotechnology, Inc., where he served as CEO from the company’s launch in 2016–2017 until his retirement in 2023 and continues as a member of the board of directors.( Under his leadership, Vir became a commercial-stage immunology company that delivered life‑saving therapies for Ebola and COVID‑19 to millions of patients and built a pipeline spanning multiple therapeutic areas.( He has also served as a director of Vir, including in his capacity as an outside board member following his CEO tenure.(

A veteran biotech leader, Scangos previously served as CEO and board member of Biogen Inc. for six years (2010–2016) and president and CEO of Exelixis, Inc. for 14 years, roles in which he helped take companies public, expand pipelines, and reshape strategic direction.( Earlier in his career he was president of Bayer Biotechnology and chair of several industry organizations, including PhRMA and the California Healthcare Institute.( He is currently a Venture Partner at ARCH Venture Partners and serves on the boards of Agilent Technologies, Voyager Therapeutics, Octave Bioscience, Rezo Therapeutics, and Life Sciences Cares.( Before entering industry, Scangos was a professor of biology at Johns Hopkins University, and he holds a B.A. in biology from Cornell University and a Ph.D. in microbiology from the University of Massachusetts, followed by postdoctoral work at Yale.( His leadership has been widely recognized; among other honors, he was named among Fortune’s “Businessperson of the Year” and Harvard Business Review’s “Best Performing CEOs in the World” in the mid‑2010s.(

Written by Perplexity from public sources.